USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/33898
Title: MARKET WITHDRAWAL MANAGEMENT OF NON-COMPLIANT MEDICINES
Authors: Jigan, Nadejda
Keywords: medicine withdrawal;pharmacovigilance;quality defects;patient safety;pharmaceutical regulation
Issue Date: 2026
Publisher: Centrul Editorial-Poligrafic Medicina
Citation: Jigan, Nadejda. MARKET WITHDRAWAL MANAGEMENT OF NON-COMPLIANT MEDICINES. In: MedEspera 2026, p. 78. ISBN 978-9975-82-486-6.
Abstract: Introduction. The withdrawal of medicines that do not meet the requirements of quality, safety, or efficacy is an essential component of the pharmacovigilance system and the protection of public health. Regulatory authorities, such as the U.S. Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency of the Republic of Moldova, constantly monitor the quality of medicines and coordinate withdrawal procedures when non-conformities are identified. The adoption of Law no. 153/2025 on medicines has contributed to updating the national legislative framework and harmonizing it with European regulations. Aim of study. Evaluation of the management mechanisms of non-compliant medicines in the Republic of Moldova and analysis of the main causes that determine these withdrawals. Methods and materials. A descriptive-analytical study was carried out based on the analysis of scientific literature published in the PubMed, Scopus, Google Scholar, and UpToDate databases in the period 2020 -2025. Forty-five cases of medicine withdrawal officially reported by AMDM in the period 2020-2025 were examined. The cases were evaluated according to the classification used internationally (Classes I, II, and III). In parallel, the provisions of the national legislative framework on post-authorization surveillance were analyzed. Results. The results indicate that the majority of withdrawals (73%, n=33) were determined by quality defects, including microbiological contamination, chemical impurities, or non-conformities in the manufacturing process. Problems associated with pharmacovigilance, such as serious adverse reactions or re-evaluation of the risk-benefit ratio, accounted for 18% (n=8), and 9% of cases were caused by labeling errors or incorrect information in the package leaflet. The average interval between notification of non-conformity and initiation of the withdrawal procedure was approximately 48-72 hours. Some difficulties were also identified regarding product traceability in the distribution chain and rapid transmission of information to health professionals. The results are comparable with the data reported in other international studies, which highlight the predominant role of quality defects in triggering withdrawal procedures. Conclusions. Quality defects are the main cause of medicine withdrawal from the market in the Republic of Moldova. Strengthening post-authorization surveillance mechanisms and optimizing traceability in the distribution chain can contribute to increasing the efficiency of the pharmacovigilance system and protecting patients' health.
metadata.dc.relation.ispartof: MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026
URI: https://medespera.md/documents/abstract-book-4.pdf
https://repository.usmf.md/handle/20.500.12710/33898
ISBN: 978-9975-82-486-6
Appears in Collections:MedEspera 2026

Files in This Item:
File Description SizeFormat 
M-078.pdf466.7 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback